Type 2 diabetes (T2D) affects more than 6% of those aged over 15 years worldwide. The condition is more prevalent in developed countries, such as the United States, where, the CDC reports, 14.7% of adults have type 2 diabetes. Having overweight or obesity increases the risk of developing the disease.
An effective treatment for type 2 diabetes is glucagon-like peptide-1 receptor agonists, or GLP-1 agonists, which are used to control blood glucose levels. They do this by stimulating insulin production, delaying stomach emptying, decreasing appetite, and inhibiting the production of glucagon — the hormone that increases blood sugar.
Most people treated with GLP-1 agonists lose weight, and significant weight loss of more than 15% of body mass can have a disease-modifying effect in people with type 2 diabetes. Two prescription-only medications, semaglutide — marketed as Wegovy in the U.S. and Ozempic in the United Kingdom — and liraglutide (sold as Saxenda in the U.K. and U.S.), have also been licensed for weight management.
Excerpted from Medical News Today